Gain Therapeutics Files 8-K, Confirms Emerging Growth Status
Ticker: GANX · Form: 8-K · Filed: Jan 31, 2024 · CIK: 1819411
| Field | Detail |
|---|---|
| Company | Gain Therapeutics, Inc. (GANX) |
| Form Type | 8-K |
| Filed Date | Jan 31, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: regulatory-filing, emerging-growth-company, corporate-governance
TL;DR
**Gain Therapeutics filed an 8-K, confirming its emerging growth company status, which means less stringent reporting requirements.**
AI Summary
Gain Therapeutics, Inc. filed an 8-K on January 31, 2024, primarily to disclose information under Regulation FD and to include financial statements and exhibits. The filing indicates that Gain Therapeutics is an emerging growth company, meaning it benefits from certain relaxed reporting requirements. This matters to investors because it signals the company's stage of development and its regulatory compliance status, which can influence perceptions of risk and future growth potential.
Why It Matters
This filing confirms Gain Therapeutics' status as an emerging growth company, which impacts its regulatory obligations and provides insights into its operational stage. Investors should note this as it affects the level of financial detail and compliance the company is subject to.
Risk Assessment
Risk Level: low — This 8-K is a routine disclosure and does not contain information that inherently increases or decreases risk for investors.
Analyst Insight
Investors should recognize that Gain Therapeutics' emerging growth company status means it may have fewer public disclosures than larger, more established companies. This requires a deeper dive into available information to fully understand its financial health and operational progress.
Key Players & Entities
- Gain Therapeutics, Inc. (company) — the registrant filing the 8-K
- January 31, 2024 (date) — date of earliest event reported and filing date
- 001-40237 (other) — Commission File Number for Gain Therapeutics, Inc.
- Delaware (other) — state of incorporation for Gain Therapeutics, Inc.
FAQ
What is the primary purpose of this 8-K filing by Gain Therapeutics, Inc.?
The primary purpose of this 8-K filing by Gain Therapeutics, Inc. is to satisfy disclosure requirements under Regulation FD and to furnish financial statements and exhibits, as indicated by 'ITEM INFORMATION: Regulation FD Disclosure' and 'ITEM INFORMATION: Financial Statements and Exhibits'.
What is the 'Date of Report' for the earliest event reported in this filing?
The 'Date of Report (Date of earliest event reported)' is January 31, 2024, as stated in the filing.
Is Gain Therapeutics, Inc. classified as an 'emerging growth company'?
Yes, Gain Therapeutics, Inc. is classified as an 'emerging growth company,' indicated by the 'x' mark next to 'Emerging growth company' in the filing.
What is the Commission File Number for Gain Therapeutics, Inc.?
The Commission File Number for Gain Therapeutics, Inc. is 001-40237, as specified in the filing.
Where is Gain Therapeutics, Inc.'s principal executive office located?
Gain Therapeutics, Inc.'s principal executive office is located at 4800 Montgomery Lane, Suite 220, Bethesda, Maryland 20814, according to the filing.
Filing Stats: 502 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2024-01-31 17:26:33
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 GANX The Nasdaq Stock Market LLC It
Filing Documents
- tm244785d1_8k.htm (8-K) — 25KB
- tm244785d1_ex99-1.htm (EX-99.1) — 26KB
- 0001104659-24-008894.txt ( ) — 231KB
- ganx-20240131.xsd (EX-101.SCH) — 3KB
- ganx-20240131_lab.xml (EX-101.LAB) — 33KB
- ganx-20240131_pre.xml (EX-101.PRE) — 22KB
- tm244785d1_8k_htm.xml (XML) — 4KB
01 Regulation FD
Item 7.01 Regulation FD On January 31, 2024, Gain Therapeutics, Inc. (the "Company") issued a press release containing a letter to the Company's stockholders from its Chief Executive Officer, Matthias Alder. A copy of the press release is furnished hereto as Exhibit 99.1 and incorporated herein by reference. The information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release of Gain Therapeutics, Inc., dated January 31, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GAIN THERAPEUTICS, INC. Dated: January 31, 2024 By: /s/ C. Evan Ballantyne Name: C. Evan Ballantyne Title: Chief Financial Officer